Rezolute Announces Alignment With FDA On Streamlined Design For Ongoing Phase 3 Trial Of Ersodetug In Tumor Hyperinsulinism

Rezolute Inc RZLT:

• REZOLUTE ANNOUNCES ALIGNMENT WITH FDA ON STREAMLINED DESIGN FOR ONGOING PHASE 3 TRIAL OF ERSODETUG IN TUMOR HYPERINSULINISM

• REZOLUTE INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026

• REZOLUTE INC - FDA CONFIRMS SUNRIZE TRIAL RESULTS EXPECTED IN DEC 2025 AS CLINCIAL EVIDENCE